To model the SMAD2/3 differences observed in TAFs, we stably knocked down SMAD2 or SMAD3 by shRNA in control fibroblasts derived from uninvolved pulmonary tissue of a randomly selected surgical lung cancer patient (#5). Here, SMAD2 is linked to lung carcinoma.